Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Forecast & Target Price

View the latest analyst price targets and forecasts to stay informed on market expectations. Click here to open.

MIRM

Mirum Pharmaceuticals Inc

Nov 29 • 03:24PM ET

45.51

Dollar change -1.14
Percentage change -2.44	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX GILD AKRO ENTA MDGL PTCT NBIX VKTX DVAX GLMD

| Held by: VTI IWM XBI VXF IWO IBB SCHA VTWO VHT IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.07	Insider Own	20.41%	Shs Outstand	46.72M	Perf Week	4.67%
Market Cap	2.18B	Forward P/E	-	EPS next Y	-0.74	Insider Trans	-0.37%	Shs Float	38.21M	Perf Month	16.16%
Income	-97.30M	PEG	-	EPS next Q	-0.30	Inst Own	94.38%	Short Float	18.25%	Perf Quarter	5.57%
Sales	307.03M	P/S	7.12	EPS this Y	58.14%	Inst Trans	-0.35%	Short Ratio	18.37	Perf Half Y	89.39%
Book/sh	4.84	P/B	9.41	EPS next Y	55.40%	ROA	-14.76%	Short Interest	6.97M	Perf Year	43.79%
Cash/sh	5.93	P/C	7.68	EPS next 5Y	-	ROE	-38.83%	52W Range	23.14 - 48.89	Perf YTD	54.17%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-39.57%	ROI	-17.75%	52W High	-6.91%	Beta	1.20
Dividend TTM	-	Quick Ratio	3.15	Sales past 5Y	88.90%	Gross Margin	73.31%	52W Low	96.67%	ATR (14)	2.04
Dividend Ex-Date	-	Current Ratio	3.34	EPS Y/Y TTM	51.94%	Oper. Margin	-30.44%	RSI (14)	60.78	Volatility	4.03% 5.27%
Employees	264	Debt/Eq	1.37	Sales Y/Y TTM	112.14%	Profit Margin	-31.69%	Recom	1.10	Target Price	62.55
Option/Short	Yes / Yes	LT Debt/Eq	1.36	EPS Q/Q	48.09%	Payout	-	Rel Volume	0.55	Prev Close	46.65
Sales Surprise	10.22%	EPS Surprise	33.24%	Sales Q/Q	89.37%	Earnings	Nov 12 BMO	Avg Volume	379.56K	Price	45.51
SMA20	5.68%	SMA50	11.64%	SMA200	33.86%	Trades		Volume	206,870	Change	-2.44%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-17-24	Initiated	Stifel	Buy	$48
Dec-18-23	Reiterated	H.C. Wainwright	Buy	$60 → $58
Nov-20-23	Resumed	JP Morgan	Overweight	$37
Nov-13-23	Initiated	Morgan Stanley	Overweight	$60
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$50
Oct-17-23	Resumed	Evercore ISI	Outperform	$62
Sep-20-23	Initiated	JMP Securities	Mkt Outperform	$70
Sep-01-22	Initiated	Citigroup	Buy	$38
Sep-20-21	Initiated	JP Morgan	Overweight	$30
Aug-07-20	Upgrade	Raymond James	Outperform → Strong Buy	$28 → $48
Aug-03-20	Initiated	H.C. Wainwright	Buy	$52
Jul-31-20	Initiated	Piper Sandler	Overweight	$77
Jun-25-20	Initiated	Robert W. Baird	Outperform	$30
Aug-12-19	Initiated	ROTH Capital	Buy	$33
Aug-12-19	Initiated	Raymond James	Outperform	$28
Aug-12-19	Initiated	Guggenheim	Buy	$18
Aug-12-19	Initiated	Evercore ISI	Outperform
Aug-12-19	Initiated	Citigroup	Buy	$21

Show Previous Ratings

Nov-14-24 08:00AM	Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLDs The Liver Meeting (Business Wire) +5.33%
Nov-13-24 02:09AM	Mirum Pharmaceuticals Inc (MIRM) Q3 2024 Earnings Call Highlights: Record Sales Surge and ... (GuruFocus.com)
Nov-12-24 09:15AM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Nov-08-24 06:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
04:30PM	Loading…
Nov-07-24 04:30PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Nov-04-24 04:30PM	Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 (Business Wire)
Oct-31-24 10:02AM	Will Mirum Pharmaceuticals, Inc. (MIRM) Report Negative Q3 Earnings? What You Should Know (Zacks)
08:30AM	Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting (Business Wire)
Oct-23-24 08:49AM	Mirum Pharmaceuticals (MIRM): A Small-Cap Biotech with Strong Sales Growth (Insider Monkey)
Oct-10-24 07:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis (Business Wire)
Oct-09-24 05:18PM	Mirum Pharmaceuticals Inc (MIRM) Q2 2024 Earnings Call Highlights: Record Sales Surge and ... (GuruFocus.com)
Sep-10-24 08:45PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-06-24 01:31PM	Four Biotech Stocks Rally Toward Buy Points As Funds Load Up (Investor's Business Daily)
11:31AM	Loading…
11:31AM	Mirum Pharmaceuticals (MIRM) Up 4.5% Since Last Earnings Report: Can It Continue? (Zacks)
Aug-28-24 04:01PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-19-24 11:06AM	Mirum (MIRM) Banks on Livmarli, Overdependence a Concern (Zacks)
Aug-09-24 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +11.79%
Aug-08-24 11:01AM	Mirum's (MIRM) Q2 Earnings Lag Estimates, Revenues Top (Zacks)
Aug-07-24 05:25PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jul-31-24 04:30PM	Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024 (Business Wire)
Jul-29-24 07:28AM	Mirum Pharmaceuticals (MIRM) Surges 7.3%: Is This an Indication of Further Gains? (Zacks)
Jul-25-24 08:30AM	Mirums LIVMARLI Now Approved for PFIC in Patients 12 Months and Older (Business Wire)
Jul-12-24 01:22PM	Health Care Stocks Give IBD 50 A Boost, And These Are Making Bullish Moves (Investor's Business Daily)
Jul-10-24 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-09-24 10:37AM	Mirum (MIRM) Gets EC Approval for Livmarli Label Expansion (Zacks)
Jul-08-24 11:38AM	Mirum (MIRM) Rises More Than 30% in Past 3 Months: Here's Why (Zacks)
08:30AM	Mirum Pharmaceuticals LIVMARLI Approved in the European Union for Patients with PFIC (Business Wire)
02:26PM	Loading…
Jun-28-24 02:26PM	MercadoLibre, A Few Other Growth Stocks, Among New Faces In IBD 50 (Investor's Business Daily)
08:30AM	Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX (Business Wire)
Jun-25-24 11:31AM	Biotech Stock Explodes On Drug Trial News As Sales Keep Doubling (Investor's Business Daily)
Jun-18-24 11:14AM	Mirum (MIRM) Soars on Interim Data From Liver Disease Studies (Zacks) -11.36%
05:46AM	Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock? (Zacks)
Jun-17-24 08:00AM	Mirums Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies (Business Wire) +27.31%
Jun-16-24 05:00PM	Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024 (Business Wire)
Jun-10-24 10:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-07-24 11:30AM	Why Is Mirum Pharmaceuticals (MIRM) Down 3.4% Since Last Earnings Report? (Zacks)
Jun-06-24 09:30AM	Long-Term Data from Mirums LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress (Business Wire) -5.10%
Jun-05-24 04:05PM	Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
Jun-03-24 06:46AM	EMA CHMP endorses Mirum Pharmaceuticals LIVMARLI for PFIC (Pharmaceutical Technology) +5.49%
May-31-24 08:30AM	Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older (Business Wire)
May-29-24 08:30AM	Long-Term Data from Mirums LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress (Business Wire)
May-28-24 10:02AM	Mirum's (MIRM) Livmarli Aids Sales but Overdependence Concerns (Zacks)
May-18-24 07:00AM	Mirum Pharmaceuticals LIVMARLI Data Showcased at ESPGHAN Annual Meeting (Business Wire)
May-13-24 09:40AM	Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 07:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
01:55PM	Mirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings: Misses Revenue Forecasts, Posts Wider Net Loss (GuruFocus.com)
01:12PM	Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating (MT Newswires)
May-09-24 11:46AM	Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates (Zacks)
07:40AM	Q1 2024 Mirum Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:49AM	Mirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings Call Transcript Highlights: Soaring Sales and ... (GuruFocus.com)
May-08-24 04:02PM	Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
May-07-24 04:10PM	Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference (Business Wire)
11:29AM	Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:30AM	Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC (Business Wire)
May-02-24 02:33PM	Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management (Newsfile)
May-01-24 04:10PM	Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 (Business Wire)
Apr-25-24 10:02AM	Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-10-24 09:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-02-24 08:30AM	Mirum Pharmaceuticals LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canadas CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome (Business Wire)
Mar-29-24 11:30AM	Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-25-24 11:46PM	Mirum Pharmaceuticals Inc (MIRM) Insider Sells Shares (GuruFocus.com)
07:00AM	Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors (GlobeNewswire)
Mar-15-24 09:32AM	Mirum's (MIRM) Livmarli Receives FDA Nod for Expanded Use (Zacks)
Mar-13-24 06:00PM	Mirum Pharmaceuticals LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (Business Wire)
Mar-08-24 07:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-05-24 08:00AM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Feb-29-24 11:34AM	Mirum's (MIRM) Q4 Earnings Lag Estimates, Revenues Beat (Zacks)
09:49AM	Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q4 2023 Earnings Call Transcript (Insider Monkey)
08:30AM	Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirums LIVMARLI (Business Wire)
Feb-28-24 05:35PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:38PM	Mirum Pharmaceuticals Inc (MIRM) Reports Robust Revenue Growth and Expanding Commercial ... (GuruFocus.com)
04:03PM	Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update (Business Wire)
Feb-21-24 04:05PM	Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024 (Business Wire)
Feb-09-24 09:15PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.97%
Feb-05-24 07:00AM	NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer (GlobeNewswire)
Jan-23-24 11:44AM	Mirum (MIRM) Banks on Livmarli Sales Despite Recent Setback (Zacks)
Jan-19-24 09:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-16-24 08:30AM	Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer (Business Wire)
Jan-15-24 04:03AM	Should You Invest in Mirum Pharmaceuticals (MIRM)? (Insider Monkey)
Jan-10-24 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.91%
Jan-08-24 08:30AM	Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates (Business Wire)
Jan-03-24 08:45AM	Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-18-23 01:05PM	United States Steel, NIO rise; Masonite, Mirum Pharmaceuticals fall, Monday, 12/18/2023 (Associated Press Finance) -15.87%
08:37AM	Mirum Pharma's liver disease therapy fails in mid-stage study (Reuters)
08:30AM	Mirum Pharmaceuticals Announces Data from EMBARK Phase 2b Study for Biliary Atresia (Business Wire)
Dec-08-23 07:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-30-23 09:45AM	Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management (Newsfile)
Nov-20-23 04:05PM	Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference (Business Wire)
Nov-13-23 02:00PM	Mirum Pharmaceuticals Presents New Data at The Liver Meeting (Business Wire) +6.57%
Nov-10-23 05:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-06-23 09:10AM	Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-03-23 08:30AM	Mirum Pharmaceuticals to Present at the 2023 UBS Biopharma Conference (Business Wire) +5.67%
Nov-02-23 07:13PM	Mirum Pharmaceuticals Inc (MIRM) Reports Q3 2023 Revenue of $47.7 Million, Up 154% YoY (GuruFocus.com)
04:05PM	Mirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Oct-30-23 10:00AM	NeoGenomics (NEO) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
08:30AM	Mirum Pharmaceuticals to Present New Data at The Liver Meeting (Business Wire)
Oct-27-23 08:45AM	Mirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023 (Business Wire)

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Howe Jolanda	SVP, GLOBAL CONTROLLER	Nov 14 '24	Option Exercise	2.94	2,500	7,350	4,926	Nov 15 05:34 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Nov 14 '24	Sale	47.10	2,500	117,752	2,426	Nov 15 05:34 PM
Heron Patrick J	Director	Sep 18 '24	Buy	37.40	115	4,301	162,308	Sep 20 04:39 PM
Heron Patrick J	Director	Sep 06 '24	Buy	41.58	230	9,563	162,193	Sep 10 05:04 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jul 23 '24	Option Exercise	2.94	34,013	99,862	126,783	Jul 24 05:32 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jul 02 '24	Sale	34.00	375	12,750	2,426	Jul 03 06:19 PM
Vig Pamela	CHIEF SCIENTIFIC OFFICER	Jun 24 '24	Option Exercise	2.94	30,559	89,721	57,965	Jun 25 05:15 PM
Vig Pamela	CHIEF SCIENTIFIC OFFICER	Jun 24 '24	Sale	34.00	30,559	1,039,006	27,406	Jun 25 05:15 PM
Ramasastry Saira	Director	Jun 05 '24	Option Exercise	14.12	5,000	70,600	5,000	Jun 07 06:20 PM
Ramasastry Saira	Director	Jun 05 '24	Sale	25.68	5,000	128,400	0	Jun 07 06:20 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Mar 27 '24	Buy	24.80	2,000	49,600	14,000	Mar 27 08:47 PM
Radovich Peter	PRESIDENT AND COO	Mar 25 '24	Sale	25.80	4,303	111,017	29,013	Mar 25 05:41 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Mar 18 '24	Buy	25.80	2,000	51,600	12,000	Mar 18 05:34 PM
Vig Pamela	CHIEF SCIENTIFIC OFFICER	Feb 02 '24	Sale	26.19	1,214	31,797	28,691	Feb 05 09:12 PM
Longpre Lara	CHIEF DEVELOPMENT OFFICER	Feb 02 '24	Sale	26.19	847	22,184	104,407	Feb 05 09:10 PM
Radovich Peter	PRESIDENT AND COO	Feb 02 '24	Sale	26.19	1,790	46,883	34,695	Feb 05 09:05 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Feb 02 '24	Sale	26.19	6,013	157,491	104,112	Feb 05 09:04 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Feb 02 '24	Sale	26.19	735	19,251	1,759	Feb 02 09:28 PM
Radovich Peter	CHIEF OPERATING OFFICER	Jan 08 '24	Sale	28.03	1,408	39,473	36,485	Jan 09 08:28 PM
Longpre Lara	CHIEF DEVELOPMENT OFFICER	Jan 08 '24	Sale	28.04	1,019	28,568	105,254	Jan 09 08:25 PM
Vig Pamela	HEAD OF RESEARCH & DEVELOPMENT	Jan 08 '24	Sale	28.03	1,408	39,472	29,905	Jan 09 08:21 PM
Peetz Christopher	PRESIDENT AND CEO	Jan 08 '24	Sale	28.03	5,209	146,033	110,125	Jan 09 08:12 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jan 08 '24	Sale	28.04	528	14,803	722	Jan 09 08:09 PM
Howe Jolanda	SVP, Global Controller	Dec 05 '23	Option Exercise	2.94	2,500	7,350	2,500	Dec 06 05:16 PM
Howe Jolanda	SVP, Global Controller	Dec 05 '23	Sale	32.40	2,500	81,000	0	Dec 06 05:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MIRM

Mirum Pharmaceuticals Inc

Upgrade your FINVIZ experience